SCHEMBL2270993

SCHEMBL2270993

Cc1ccc(C2CCC(C3CCC(C=O)CC3)CC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 1/20 0.41
MAP1LC3B Q9GZQ8 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
ATM Q13315 1/20 0.38
HDAC2 Q92769 1/20 0.36
ESR2 Q92731 2/20 0.35
CYP2A6 P11509 1/20 0.33
DRD2 P14416 1/20 0.33
DRD4 P21917 1/20 0.33
DRD3 P35462 1/20 0.33
USP5 P45974 1/20 0.32
NPC1 O15118 1/20 0.32
TSHR P16473 1/20 0.32
RAB9A P51151 1/20 0.32
SLC2A1 P11166 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270988 1.00 SLC18A3 (0.41) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL2270991 1.00 SLC18A3 (0.41) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL7046277 0.94 SLC18A3 (0.44) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL7046275 0.94 SLC18A3 (0.44) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL7882916 0.85 FFAR1 (0.44) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL6853901 0.84 HDAC2 (0.43) HDAC2ESR2NPC1RAB9A
SCHEMBL14140574 0.84 LMNA (0.40) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL20967223 0.82 SLC18A3 (0.41) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL9182846 0.82 SLC2A1 (0.41) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53
SCHEMBL2272215 0.82 SLC18A3 (0.41) SLC18A3MAP1LC3BSMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2020407-B1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF JNC CORP (JP) 2013-07-03 EP disclosed
US-7999123-B2 2-oxetanone derivative and process for production thereof JNC CORPORATION (JP) 2011-08-16 US disclosed
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF CHISSO CORPORATION (JP) 2009-11-05 US disclosed
EP-2020407-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF Chisso Corporation (JP) 2009-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275756-A1 2-OXETANONE DERIVATIVE AND PROCESS FOR PRODUCTION THEREOF OGDH, OXGR1, OXER1 SLC18A3 2298/4885MAP1LC3B 3038/4885SMN1; SMN2 4528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.